肝硬化中细胞治疗的状态和候选物：克服晚期肝硬化中的“

StephenW

Journal of Gastroenterology

February 2017, Volume 52, Issue 2, pp 129-140
Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis

    Authors
    Authors and affiliations

    Shuji TeraiEmail authorAtsunori Tsuchiya

    Shuji Terai
        1Email author
    Atsunori Tsuchiya
        1

    1.Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan

Review

First Online:
    08 September 2016

DOI: 10.1007 / s00535-016-1258-1

Cite this article as:
    Terai, S. & Tsuchiya, A. J Gastroenterol (2017) 52: 129. doi: 10.1007 / s00535-016-1258-1

    661 Downloads

Abstract

The treatment of liver cirrhosis is currently being standardized and developed specifically to reduce activation of hepatic stellate cells (HSCs), inhibit fibrosis, increase degradation of matrix components, and reduce activated myofibroblasts. Cell therapy can be applied in the treatment of liver cirrhosis; , The characteristic features of this therapy differ from those of other treatments because of the living of a living body origin and production of multiple cytokines, chemokines, matrix metalloproteinases (MMPs), and growth factors. Thus, cell therapies can potentially have multiple effects on The damaged molecular, including alleviating liver cirrhosis and stimulating liver growth with affecting the host cells. Cell therapies initially involved autologous bone marrow cell infusion, and have recently developed to include the use of specific cells such as mesenchymal stem cells and macrophages. The associated molecular Mechanisms, routes of administration, possibility of allogeneic cell therapy, and host conditions suitable for cell therapies are now being extensively analyzed. In this review, we summarize the status and future prospects of cell therapy for liver cirrhosis.
Keywords
Liver cirrhosisMesenchymal stem cell Macrophages Cell therapy

StephenW

胃肠病学杂志

2017年2月，第52卷，第2期，第129-140页
肝硬化中细胞治疗的状态和候选物：克服晚期肝硬化中的“不可逆点”

作者
作者和关系

Shuji TeraiEmail作者Ansunori Tsuchiya

Shuji Terai
1电子邮件作者
Atsunori Tsuchiya
1

日本新泻大学医学及牙科学研究科胃肠病学与肝病学教室

评论

首先在线：
08 September 2016

DOI：10.1007 / s00535-016-1258-1

引用本文：
Terai，S.＆Tsuchiya，A.J Gastroenterol（2017）52：129。doi：10.1007 / s00535-016-1258-1

661下载

抽象

肝硬化的治疗目前正在标准化并专门开发以减少肝星状细胞（HSC）的活化，抑制纤维化，增加基质组分的降解，并减少活化的肌成纤维细胞。细胞治疗可用于治疗肝硬化;由于活体起源和多种细胞因子，趋化因子，基质金属蛋白酶（MMP）和生长因子的产生，这种治疗的特征与其它治疗的特征不同。因此，细胞疗法可能对受损分子具有多种作用，包括减轻肝硬化和刺激肝脏生长并影响宿主细胞。细胞疗法最初涉及自体骨髓细胞输注，并且最近已发展成包括使用特异性细胞例如间充质干细胞和巨噬细胞。相关分子机制，给药途径，同种异体细胞治疗的可能性和适于细胞治疗的宿主条件现在正在被广泛分析。在本综述中，我们总结了肝硬化细胞治疗的状态和未来前景。
关键词
肝硬化间充质干细胞巨噬细胞

StephenW

http://link.springer.com/article ... =alerts.TOCjournals

MP4

充质干细胞中国很早开始用于治疗了，俄罗斯和英国都有报道